

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## The Proximal Hamstring Avulsion Clinical Trial (PHACT)- a randomised controlled non-inferiority trial of operative versus non-operative treatment of proximal hamstrings avulsions: study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031607
Article Type:	Protocol
Date Submitted by the Author:	11-May-2019
Complete List of Authors:	<p>Pihl, Elsa; Karolinska Institutet, Karolinska Institutet Danderyds Sjukhus  Holen Kristoffersen, Målfrid; Haukeland University Hospital, Department of Orthopaedic Surgery  Rosenlund, Anne-Mari; Oslo University Hospital, Division of Orthopaedic Surgery  Lazlo, Sofia; Uppsala University Hospital, Department of Surgical Sciences  Berglöf, Mida; Karolinska Institutet, Karolinska Institutet Danderyds Sjukhus  Ribom, Eva; Uppsala University Hospital, Department of Surgical Sciences  Eriksson, Karl; Karolinska Institute, Department of clinical science and education Södersjukhuset  Frihagen, Frede; Oslo University Hospital, Division of Orthopaedic Surgery  Mattila, Ville; Tampereen yliopistollinen sairaala Tuki ja liikuntaelinsairauksien vastuualue  Schilcher, Jörg; Linköping University Hospital, Department of Orthopaedic Surgery and Department of Clinical and Experimental Medicine  Eklund, Martin; Karolinska Institutet,  Snellman, Greta; Uppsala University Hospital, Department of Surgical Sciences  Skorpil, Mikael; Karolinska Institutet, Department of Molecular Medicine and Surgery  Sköldenberg, Olof; Karolinska Institute, Department of Clinical Sciences, Danderyd Hospital  Hedbeck, Carl Johan; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital  Jonsson, Kenneth; Uppsala University Hospital, Department of Surgical Sciences</p>
Keywords:	Hamstring, Hamstring Tendons, Randomized Controlled Trial, Magnetic resonance imaging < RADIOLOGY & IMAGING, Patient reported Outcome Measure, Muscle strength



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# The Proximal Hamstring Avulsion Clinical Trial (PHACT)- a randomised controlled non-inferiority trial of operative versus non-operative treatment of proximal hamstrings avulsions: study protocol

---

## Authors:

Elsa Pihl<sup>1</sup>, Målfrid Holen Kristoffersen<sup>2</sup>, Anne-Mari Rosenlund<sup>3</sup>, Sofia Laszlo<sup>4</sup>, Mida Berglöf<sup>1</sup>, Eva Ribom<sup>4</sup>, Karl Eriksson<sup>5</sup>, Frede Frihagen<sup>3</sup>, Ville M Mattila<sup>6</sup>, Jörg Schilcher<sup>7</sup>, Martin Eklund<sup>8</sup>, Greta Snellman<sup>4</sup>, Mikael Skorpil<sup>9</sup>, Olof Sköldenberg<sup>1</sup>, Carl Johan Hedbeck<sup>1</sup>, Kenneth B Jonsson<sup>4</sup>.

<sup>1</sup> Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Orthopaedics, SE-171 77 Stockholm, Sweden

<sup>2</sup> Department of Orthopaedic Surgery, Haukeland University Hospital, N 5021 Bergen, Norway.

<sup>3</sup> Division of Orthopaedic Surgery, Oslo University Hospital, N-0450 Oslo, Norway.

<sup>4</sup> Department of Surgical Sciences, Uppsala University Hospital, SE-751 85 Uppsala, Sweden

<sup>5</sup> Karolinska Institutet Department of clinical science and education Södersjukhuset, Department of Orthopaedics Södersjukhuset, SE-188 83 Stockholm, Sweden

<sup>6</sup> Department of Orthopaedics, Tampere University Hospital, F-33321, Tampere, Finland

<sup>7</sup> Department of Orthopaedic Surgery and Department of Clinical and Experimental Medicine, University Hospital Linköping, SE-58185 Linköping, Sweden

<sup>8</sup> Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, SE-171 77 Stockholm, Sweden

<sup>9</sup> Karolinska Institutet, Department of Molecular Medicine and Surgery, SE-171 77 Stockholm, Sweden

**Word count: 3939**

**Corresponding author:**

**Dr Elsa Pihl; [elsa.pihl@ki.se](mailto:elsa.pihl@ki.se)**

## Abstract

**Introduction:** The treatment of proximal hamstring avulsions is controversial. While several trials have investigated the outcome for patients treated surgically, there is today no prospective trial comparing operative treatment with non-operative treatment. This protocol describes the design for the Proximal Hamstring Avulsion Clinical Trial (PHACT) - the first randomized controlled trial of operative versus non-operative treatment for proximal hamstring avulsions.

**Methods and analysis:** PHACT is a multicentre randomised controlled trial conducted across Sweden, Norway and Finland. Eligible patients (60 participants/treatment arm) with a proximal hamstring avulsion of at least two of three tendons will be randomized to either operative or non-operative treatment. Participants allocated to surgery will undergo reinsertion of the tendons with suture anchors. The rehabilitation program will be the same for both treatment groups. When patient or surgeon equipoise for treatment alternatives cannot be reached and randomization therefore is not possible, patients will be invited to participate in a parallel observational non-randomized cohort. The primary outcome will be the patient reported outcome measure Perth Hamstring Assessment Tool at 24 months. Secondary outcomes include the Lower Extremity Functional Score, physical performance and muscle strength tests, patient satisfaction and MR imaging. Data analysis will be blinded and intention-to-treat analysis will be preformed.

**Ethics and dissemination:** Ethical approval has been granted by the Ethical Committee of Uppsala University (DNR: 2017-170) and by the Norwegian ethical board (REC: 2017/1911). The study will be conducted in agreement with the Helsinki declaration. The findings will be disseminated in peer-reviewed publications.

**This study is registered at ClinicalTrials.gov**

Trial Registration Number: NCT03311997

Recruitment Status: Recruiting

First Posted: October 2017

Last update posted February 2019

**Strength and limitations of this study**

- This is the first randomized clinical trial on operative versus non-operative treatment of proximal hamstring avulsions.
- The multicentre design including patients from different healthcare regions across Sweden, Norway and Finland will support external validity and implementation.
- The treatment outcome will be assessed with a hamstring specific validated PROM and objective functional tests and imaging.
- Owing to the type of interventions, blinding of the patients and treatment providers is not possible.

**Introduction**

The treatment of proximal hamstring avulsions is controversial. The literature suggests that surgical treatment is the treatment of choice. For example, in a recent systematic review by Bodendorfer et al.<sup>1</sup> it is claimed that surgically treated patients have better results in psychometric scores, functional- and strength tests than non-surgically treated patients. However, existing literature may be biased. The studies conducted so far are mainly retrospective case series<sup>1-2</sup> and have only occasionally used validated outcome measures, such as Harris Hip Score<sup>3</sup> and Lower Extremity Functional Scale<sup>3-5</sup>. The Perth Hamstring Assessment Tool (PHAT)<sup>6</sup> is designed and validated for follow up of patients with hamstring avulsion<sup>6</sup>, but was only recently developed.

Bodendorfer et al.<sup>1</sup> only found 28 non-surgical treated patients compared to 767 surgical treated patients to include in their review, suggesting a publication bias in the existing literature and providing limited power for comparisons between the surgically and non-surgically treated patients. In the light of the apparent lack of comparative studies one needs to be aware of surgical complication rates when suggesting operative treatment. With

1  
2  
3 a reported aggregated complication rate as high as 23% in the surgically treated group <sup>1</sup>,  
4 surgery cannot be considered harmless.

5  
6  
7 The aim of this prospective, multicentre, randomized controlled trial is to provide  
8 reliable evidence on how to treat physically active patients, 30 to 70 years of age, with  
9 proximal hamstring avulsions. We will use PHAT <sup>6</sup> at 24 months post treatment allocation as  
10 our primary outcome measure.  
11  
12  
13

## 14 15 16 **Methods and analysis**

### 17 18 19 **Study design and setting**

20  
21 The Proximal Hamstring Avulsion Clinical Trial (PHACT) is a multicentre, prospective,  
22 preference-tolerant, randomised, controlled, non-inferiority trial with two treatment arms.  
23 The protocol was developed in accordance with Standard Protocol Items: Recommendations  
24 for Interventional Trials and Template for Intervention Description and Replication  
25 statements <sup>7 8</sup>.

26  
27 The study is conducted in cooperation with Swedish Orthopaedic Trauma Society and  
28 has eleven study sites at orthopaedic departments across Sweden, Norway and Finland.  
29 Inclusion started in September 2017 and recruitment is expected to finalise in 2021, which  
30 would allow for read-out of the primary endpoint in 2023.  
31  
32  
33

### 34 35 36 37 38 **Recruitment strategy**

39  
40 Patients with proximal hamstring avulsions that are diagnosed or referred to the  
41 orthopaedic department at one of the eleven hospitals will be screened for participation in  
42 the study. Eligible patients are invited to participate and provided with oral and written  
43 information. Thereafter patients are asked to sign a written informed consent statement  
44 before any study procedure occurs.  
45  
46  
47  
48  
49

### 50 51 52 **Patients**

53  
54 Patients must fulfil all the inclusion criteria and must not have any exclusion criteria to be  
55 eligible for randomization.  
56

- 57 • Age at injury between 30 and 70 years
- 58  
59  
60

- Physical examination supports the diagnosis; e.g. a positive hip extension test, palpable defect and/or local tenderness and hematoma
- MRI shows a complete acute avulsion of at least two of three tendons from the footprint at the ischial tuberosity
- Patient has a moderate to high activity level
- Patient has linguistic and mental ability to understand the rehabilitation program explained in Swedish, Norwegian, Finnish or English
- Time from injury to inclusion in study is less than 4 weeks

### ***Exclusion criteria***

- Diabetes with secondary complications
- Previous major lower extremity injury or disease with sequelae
- Moderate or severe liver, pulmonary, kidney, psychiatric or heart disease that significantly increases the risk of complications after operative treatment
- Severe obesity (BMI>35)
- Alcohol or substance abuse
- High energy injury or combinations of injuries affecting the lower extremity

### ***Intervention***

We will randomly assign patients to either operative treatment (n=60) with suture anchor reinsertion of the tendons to the footprint at the ischial tuberosity or to non-operative treatment (n=60). Both groups will follow the same standardized rehabilitation protocol.

To minimize bias by indication, we will offer the patients that are eligible but where patient or doctor equipoise to treatment cannot be reached to participate in a parallel follow up cohort with identical treatment options and follow-up. In the parallel cohort, the patients/surgeons preferred treatment is provided.

### ***Surgical procedure***

Patients allocated to the operative group will undergo surgery at the earliest convenient time but no later than 6 weeks after the injury. The surgeon may choose whether to make a longitudinal or transversal skin incision. The proximal ends of the avulsed tendons are



1  
2  
3 identified and after dissection they are reattached to the ischial tuberosity using at least two  
4 suture anchors.  
5

### 6 7 **Rehabilitation**

8  
9  
10 The rehabilitation protocol is based on a previously published rehabilitation protocol<sup>9</sup> and  
11 will be the same for both treatment allocations. In brief: No brace is used. Full weight  
12 bearing is allowed. The patients are instructed to keep their stride length short<sub>2</sub> and to avoid  
13 sitting and any motion that stretches the hamstring for the first three weeks. Patients are  
14 instructed to perform isometric exercises of the quadriceps and gluteal muscles to avoid  
15 muscle atrophy. After two weeks, isometric contractions of the hamstring muscles are  
16 allowed and progressed with cautious dynamic exercises during week four. Specific  
17 hamstring strengthening exercises are begun after five weeks.  
18  
19  
20  
21  
22  
23  
24

### 25 **Study outcomes**

#### 26 **Primary outcome**

27  
28 The primary outcome measure will be the patient reported PHAT score<sup>6</sup> at 24 months. PHAT  
29 is a condition specific questionnaire with maximum score 100, with a higher score  
30 corresponding to higher function. The questionnaire uses a visual analogue scale for pain  
31 scores during different activities, as well as categorical scores for activity levels and  
32 tenderness<sub>2</sub> and has been shown to be sensitive to clinical changes<sup>10</sup>.  
33  
34  
35  
36  
37  
38  
39

#### 40 **Secondary outcomes**

##### 41 *Additional patient reported outcomes*

42  
43 The Lower Extremity Functional Scale (LEFS)<sup>11</sup> will be used to assess patient reported  
44 outcome. LEFS is a reliable, valid and responsive tool for assessing functional status in  
45 several populations with lower extremity musculoskeletal conditions<sup>11 12</sup>. Information  
46 regarding physical activity level will be collected using the short form of International  
47 Physical Activity Questionnaire, IPAQ-SF<sup>13 14</sup>. Furthermore, data on general satisfaction,  
48 return to work and return to sports will be collected.  
49  
50  
51  
52  
53

##### 54 *Functional tests and muscle strength tests*

55  
56 The functional performance will be assessed through the timed step test<sup>15</sup>, which is a test  
57 previously validated for knee arthroplasty patients and the single leg hop test, which is a  
58 performance-based test validated in anterior cruciate ligament trials<sup>16</sup>. Measurement of  
59  
60

1  
2  
3 maximum kinetic force (Newton, N) will be conducted using a handheld isometric  
4 dynamometer (microFET 2; Hoggan health industries)<sup>17</sup>. Study sites equipped with a  
5 computer based isokinetic dynamometer, BiodexTM<sup>18 19</sup>, will assess peak torque (N) and  
6 total workload (Joule, J) of the hamstrings. All strength and functional performance tests will  
7 be reported with ratio of injured/uninjured leg, with the uninjured leg serving as reference  
8 for each subject.  
9

### 10 11 12 *Imaging outcomes*

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Magnetic Resonance Imaging, MRI, will be used at 24 months to evaluate the entire thigh  
muscle volume and to assess muscle and tendon quality. We will use the uninjured side as  
reference for each subject.

### **Data collection procedure**

Follow-up visits are planned at 3, 6, 12 and 24 months. A study nurse will provide a set of  
questionnaires for the patients to fill out. The nurse will also scan the patients' charts for  
adverse events or complications. A physiotherapist that is blinded to the intervention will  
perform the strength and functional test at 6, 12 and 24 months. At the 24-month follow-up,  
MRI of both thighs will be performed.

### **Sample size**

Taking into account the cost and risks associated with surgery, and the fact that the  
literature clearly recommends surgery, a non-inferiority design was considered appropriate.  
Thus, the study aims to demonstrate that non-operative treatment is no worse than  
operative treatment by more than the non-inferiority margin.

Based on the existing literature the standard deviation of PHAT measurements is  
approximately 16-21<sup>6 20</sup>. A reasonable non-inferiority margin is half of the standard  
deviation and this effect size is lower than the minimal detectable change of the PHAT<sup>6</sup>. To  
achieve 85% power, with  $\alpha=0.5$ , for demonstrating non-inferiority using a non-inferiority  
margin of 10, 50 patients in each arm are required. Heterogeneity of treatment effects is  
likely in surgical interventions and is best handled by increasing power. Some crossover and  
loss to follow-up will occur. For these reasons, we will continue inclusion until at least 60  
patients in each group has initiated treatment.

### Randomisation procedure

The REDCap (REDCap Software TM) randomization tool will be used to facilitate randomisation <sup>21</sup>. Allocation tables with a random block size (2-6), stratified by study site, were created by a statistician and uploaded blinded into the REDCap project. The randomisation is permanent and not editable within the participant record and, like all other activity within REDCap, is tracked and not modifiable in the audit log.

### Blinding

To minimize ascertainment bias this trial is single-blinded, where the physiotherapist conducting strength and functional tests at 6, 12 and 24 months will be blinded to the intervention, by informing the patients not to tell and asking them to wear clothes concealing the surgery scar. The statistician analysing the data will also be blinded to treatment arms.

### Data management

All study data will be collected and managed in a digital case report form, CRF, using REDCap electronic data capture tools hosted at Karolinska Institutet. REDCap is a secure, web-based application supporting data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. <sup>21</sup>

Data will be kept securely in order to protect confidentiality before, during and after the trial. A codebook matching the personal identification number and the trial identification number is kept at each study site and the trial identification number is noted in the patient's electronic chart. The study nurses and investigators can log on and enter data directly into the database. Patients will complete surveys at each visit. Any paper forms used are stored for cross checking at each study site.

### Statistical analysis plan

The flow of patients through the trial is displayed in a CONSORT diagram (Figure 1). The number of patients screened for trial entry; those who are ineligible and the reasons why; number of eligible patients not providing consent; and the number of eligible patients

1  
2  
3 subsequently randomised will be presented. The characteristics of the screened population,  
4 the ineligible participants, and eligible participants who consent and do not consent will be  
5 summarised. Information regarding the number of surgeons and centres, as well as number  
6 of patients treated by each surgeon will be provided. Data on patient eligibility and reasons  
7 for withdrawal from treatment or the trial will be summarised. Baseline patient  
8 characteristics will be summarized using descriptive statistics; counts for categorical  
9 variables and mean/median and inter-quartile range for continuous variables.  
10  
11  
12  
13  
14  
15

16 Primary analyses will be by intention-to-treat. However, since ITT analyses can be anti-  
17 conservative for non-inferiority trials, we will also conduct per-protocol and as-treated  
18 analyses. Cases will only be considered treatment cross-overs if the randomly assigned  
19 treatment is changed by patient preferences. Non-operative treated patients that are  
20 treated operatively due to late complaints (>3 mo. after inclusion) will not be considered  
21 cross-overs.  
22  
23  
24  
25  
26

27 All analyses will be conducted blinded for treatment allocation. All statistical tests will  
28 be two-sided with an  $\alpha$  of 0.05. Differences between groups in continuous skewed main  
29 outcome variables will be analysed by the Mann-Whitney U-test, and by the t-test when  
30 variables are from a symmetrical distribution. Results will be presented with 95% confidence  
31 intervals. Two-way-tables with the chi-square test will be used for dichotomous variables.  
32  
33 No adjustment of p-values for multiple comparisons (secondary analyses) will be  
34 undertaken.  
35  
36  
37  
38  
39

40 In secondary analyses, multivariate regression models will be used to analyse the  
41 primary outcome (PHAT score at 24 months follow-up). The main variables of interest  
42 included are; the intervention, age, sex, study site and the degree of tendon retraction. We  
43 will also jointly analyse all timepoints in a linear mixed model (to adjust for within-patient  
44 correlations). Patients will be treated as a random effects, and time points, randomization  
45 arm, age at baseline, sex, and degree of tendon retraction will be included as fixed effects.  
46  
47 As further secondary analyses, the randomized and observational cohorts will be analysed  
48 together using propensity scores adjustment (the randomized patients will get propensity  
49 score 0.5). The propensity score will be based on age, sex, study site, IPAQ and the degree of  
50 tendon retraction.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We will test for heterogeneity of treatment effects by testing for significant  
4 interactions in the following subgroups: Tendon retraction  $> 2$  cm vs  $\leq 2$  cm and age  $> 50$   
5 years vs  $\leq 50$  years.  
6  
7

8  
9 Missing data can occur in two different ways in the study: (1) Questions in the PHAT  
10 questionnaire can be left unanswered; and (2) patients can miss specific follow-up visits or  
11 drop out of the study altogether. Missing PHAT score questions will be imputed based on the  
12 answered questions. Missed follow-up visit at 24 months will be handled using a multiple  
13 imputed model for the primary analysis. The multiple imputation protocol will be based on a  
14 longitudinal model for predicting PHAT at 24 months based on the PHAT score recorded at  
15 previous time points together with patient age, sex, and degree of tendon retraction. The  
16 mixed effects model handles data missing at random seamlessly and no imputation will be  
17 needed for that specific analysis. We will test the robustness of the results to data not  
18 missing at random by assuming a missingness model where missingness is associated with  
19 PHAT score.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Adverse events and complications**

31 At follow-up, questions with the aim of identifying adverse events and serious adverse  
32 events will be provided. Medical records will also be checked for adverse effects. Undesired  
33 events such as surgical site infections, neurological sequelae, thromboembolism, re-rupture  
34 or failure and hypertrophic scarring in surgical patients are defined as adverse effects.  
35 Serious adverse effects are defined as events resulting in death, hospitalization or  
36 threatening life, i.e. pulmonary embolism, sepsis or cardiovascular complications.  
37  
38  
39  
40  
41  
42

### 43 **Patient involvement**

44 Patients were not formally involved in designing the study protocol. In the process of  
45 designing the study protocol and selecting the primary outcome a few patients were  
46 interviewed in clinical practice. Patients have been invited to participate in monitor meeting  
47 with researchers from the participating sites present. The participants will receive a written  
48 summary of main findings when the study is finished.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Ethics and dissemination

Ethical approval has been granted by the Ethical Committee of Uppsala University (DNR: 2017-170) and the Norwegian Regional Ethical Committee (REC: 2017/1911). The study will be conducted in agreement with the Helsinki declaration.

As both treatment options are accepted in the catchment area for the study, the randomization procedure was deemed ethically acceptable. The results will provide evidence-based treatment algorithms for future patients.

The primary study results will be submitted for publication to an international, peer-reviewed journal, regardless of whether the results are positive, negative or inconclusive in relation to the study hypothesis.

## References

1. Bodendorfer BM, Curley AJ, Kotler JA, et al. Outcomes After Operative and Nonoperative Treatment of Proximal Hamstring Avulsions: A Systematic Review and Meta-analysis. *The American journal of sports medicine* 2017;363546517732526. doi: 10.1177/0363546517732526
2. van der Made AD, Wieldraaijer T, Kerkhoffs GM, et al. The hamstring muscle complex. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA* 2015;23(7):2115-22. doi: 10.1007/s00167-013-2744-0 [published Online First: 2013/11/06]
3. Chahal J, Bush-Joseph CA, Chow A, et al. Clinical and magnetic resonance imaging outcomes after surgical repair of complete proximal hamstring ruptures: does the tendon heal? *The American journal of sports medicine* 2012;40(10):2325-30. doi: 10.1177/0363546512453298
4. Hofmann KJ, Paggi A, Connors D, et al. Complete Avulsion of the Proximal Hamstring Insertion: Functional Outcomes After Nonsurgical Treatment. *The Journal of bone and joint surgery American volume* 2014;96(12):1022-25. doi: 10.2106/jbjs.m.01074 [published Online First: 2014/06/22]
5. Skaara HE, Moksnes H, Frihagen F, et al. Self-reported and performance-based functional outcomes after surgical repair of proximal hamstring avulsions. *The American journal of sports medicine* 2013;41(11):2577-84. doi: 10.1177/0363546513499518 [published Online First: 2013/08/31]
6. Blakeney WG, Zilko SR, Edmonston SJ, et al. Proximal hamstring tendon avulsion surgery: evaluation of the Perth Hamstring Assessment Tool. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA* 2017;25(6):1936-42. doi: 10.1007/s00167-016-4214-y
7. Hoffmann TC, Glasziou PP, Boutron I, et al. [Better Reporting of Interventions: Template for Intervention Description and Replication (TIDieR) Checklist and Guide]. *Gesundheitswesen* 2016;78(3):e174. doi: 10.1055/s-0037-1600948 [published Online First: 2016/03/01]

- 1  
2  
3 8. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard  
4 protocol items for clinical trials. *Rev Panam Salud Publica* 2015;38(6):506-14.  
5 [published Online First: 2016/07/22]  
6
- 7 9. Askling CM, Koulouris G, Saartok T, et al. Total proximal hamstring ruptures: clinical and  
8 MRI aspects including guidelines for postoperative rehabilitation. *Knee surgery,*  
9 *sports traumatology, arthroscopy : official journal of the ESSKA* 2013;21(3):515-33.  
10 doi: 10.1007/s00167-012-2311-0 [published Online First: 2012/12/12]  
11
- 12 10. Blakeney WG, Zilko SR, Edmonston SJ, et al. A prospective evaluation of proximal  
13 hamstring tendon avulsions: improved functional outcomes following surgical repair.  
14 *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*  
15 2017;25(6):1943-50. doi: 10.1007/s00167-017-4475-0 [published Online First:  
16 2017/03/11]  
17
- 18 11. Binkley JM, Stratford PW, Lott SA, et al. The Lower Extremity Functional Scale (LEFS):  
19 scale development, measurement properties, and clinical application. North  
20 American Orthopaedic Rehabilitation Research Network. *Physical therapy*  
21 1999;79(4):371-83. [published Online First: 1999/04/14]  
22
- 23 12. Mehta SP, Fulton A, Quach C, et al. Measurement Properties of the Lower Extremity  
24 Functional Scale: A Systematic Review. *J Orthop Sports Phys Ther* 2016;46(3):200-16.  
25 doi: 10.2519/jospt.2016.6165 [published Online First: 2016/01/28]  
26
- 27 13. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-  
28 country reliability and validity. *Medicine and science in sports and exercise*  
29 2003;35(8):1381-95. doi: 10.1249/01.Mss.0000078924.61453.Fb [published Online  
30 First: 2003/08/06]  
31
- 32 14. Lee PH, Macfarlane DJ, Lam TH, et al. Validity of the International Physical Activity  
33 Questionnaire Short Form (IPAQ-SF): a systematic review. *The international journal of*  
34 *behavioral nutrition and physical activity* 2011;8:115. doi: 10.1186/1479-5868-8-115  
35 [published Online First: 2011/10/25]  
36
- 37 15. Marmon AR, McClelland JA, Stevens-Lapsley J, et al. Single-step test for unilateral limb  
38 ability following total knee arthroplasty. *J Orthop Sports Phys Ther* 2013;43(2):66-73.  
39 doi: 10.2519/jospt.2013.4372  
40
- 41 16. Reid A, Birmingham TB, Stratford PW, et al. Hop testing provides a reliable and valid  
42 outcome measure during rehabilitation after anterior cruciate ligament  
43 reconstruction. *Physical therapy* 2007;87(3):337-49. doi: 10.2522/ptj.20060143  
44 [published Online First: 2007/02/22]  
45
- 46 17. Reurink G, Goudswaard GJ, Moen MH, et al. Strength Measurements in Acute Hamstring  
47 Injuries: Intertester Reliability and Prognostic Value of Handheld Dynamometry. *J*  
48 *Orthop Sports Phys Ther* 2016;46(8):689-96. doi: 10.2519/jospt.2016.6363 [published  
49 Online First: 2016/05/14]  
50
- 51 18. Drouin JM, Valovich-mcLeod TC, Shultz SJ, et al. Reliability and validity of the Biodex  
52 system 3 pro isokinetic dynamometer velocity, torque and position measurements.  
53 *Eur J Appl Physiol* 2004;91(1):22-9. doi: 10.1007/s00421-003-0933-0 [published  
54 Online First: 2003/09/26]  
55
- 56 19. Pincivero DM, Lephart SM, Karunakara RA. Reliability and precision of isokinetic strength  
57 and muscular endurance for the quadriceps and hamstrings. *International journal of*  
58 *sports medicine* 1997;18(2):113-7. doi: 10.1055/s-2007-972605 [published Online  
59 First: 1997/02/01]  
60



- 1  
2  
3 20. Best R, Eberle J, Beck F, et al. [Surgical Refixation after Proximal Hamstring Tendon  
4 Avulsion Injuries: Does the Time of Surgery Influence Functional Outcomes?].  
5 *Sportverletzung Sportschaden : Organ der Gesellschaft für Orthopädisch-*  
6 *Traumatologische Sportmedizin* 2017;31(3):160-66. doi: 10.1055/s-0043-113211  
7 [published Online First: 2017/09/05]  
8  
9 21. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a  
10 metadata-driven methodology and workflow process for providing translational  
11 research informatics support. *Journal of biomedical informatics* 2009;42(2):377-81.  
12 doi: 10.1016/j.jbi.2008.08.010 [published Online First: 2008/10/22]  
13  
14  
15  
16  
17

### 18 **Authors' contributions: state how each author was involved in writing the protocol.**

19  
20  
21 All authors have contributed to the design of this trial protocol. E Pihl, CJ Hedbeck and K B  
22 Jonsson have initiated the project. K B Jonsson is the primary investigator. The protocol was  
23 drafted by E Pihl and K B Jonsson and was refined by M Holen Kristofferssen, A-M  
24 Rosenlund, M Berglöf, E Ribom, K Eriksson, F Frihagen, G Snellman, J Schilcher, M Eklund, V  
25 M Mattila, M Skorpil, O Sköldenberg and CJ Hedbeck. Statistical advice was provided by  
26 Eklund. M Berglöf and E Ribom designed the protocol for physical functional tests and the  
27 rehabilitation program. M Skorpil, E Pihl and S Lazlo developed protocol for the imaging  
28 outcomes. S Lazlo was responsible for drafting the manuscript. All authors have read and  
29 approved the final manuscript.  
30  
31  
32  
33  
34  
35  
36

37 The PHACT collaborative study group consists of all local investigators who are  
38 responsible for the execution of the trial and valid data gathering. They have all read and  
39 approved the final manuscript.  
40  
41  
42  
43  
44  
45

### 46 **Funding**

47  
48 This work was supported by:

49  
50 AFA Insurance.

51  
52 Centrum för idrottsforskning, CIF, grant number (P2019-0155).

53  
54 Landstingets Ömsesidiga Försäkringsbolag, LÖF, insurance company owned by its policy  
55 owners, the Swedish counties and regions.

56  
57 Östergötland County Council.  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Competing interests statement.**

We have no competing interest to declare.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Screening

Patient with proximal hamstrings injury

**Excluded**  
-not meeting inclusion criteria  
-meeting exclusion criteria

Enrollment

Eligible participants

**Excluded**  
- do not wish to enter

Participants and doctor reaches equipoise to treatment

Yes

No

RCT

Observational cohort  
Treatment by preference

Allocation

Operative treatment

Non-operative treatment

Follow-up

3 months: PHAT, LEFS, IPAQ-SF, adverse events

6 and 12 months: PHAT, LEFS, IPAQ-SF, adverse events, physical performance

24 months: PHAT, LEFS, IPAQ-SF, adverse events, physical performance, MRI

Analysis

Primary outcome : PHAT at 24 months

# BMJ Open

## The Proximal Hamstring Avulsion Clinical Trial (PHACT)- a randomised controlled non-inferiority trial of operative versus non-operative treatment of proximal hamstrings avulsions: study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031607.R1
Article Type:	Protocol
Date Submitted by the Author:	17-Jul-2019
Complete List of Authors:	Pihl, Elsa; Karolinska Institutet, Karolinska Institutet Danderyds Sjukhus Holen Kristoffersen, Målfrid; Haukeland University Hospital, Department of Orthopaedic Surgery Rosenlund, Anne-Mari; Oslo University Hospital, Division of Orthopaedic Surgery Laszlo, Sofia; Uppsala University Hospital, Department of Surgical Sciences Berglöf, Mida; Karolinska Institutet, Karolinska Institutet Danderyds Sjukhus Ribom, Eva; Uppsala University Hospital, Department of Surgical Sciences Eriksson, Karl; Karolinska Institute, Department of clinical science and education Södersjukhuset Frihagen, Frede; Oslo University Hospital, Division of Orthopaedic Surgery Mattila, Ville; Tampereen yliopistollinen sairaala Tuki ja liikuntaelinsairauksien vastuualue Schilcher, Jörg; Linköping University Hospital, Department of Orthopaedic Surgery and Department of Clinical and Experimental Medicine Eklund, Martin; Karolinska Institutet, Snellman, Greta; Uppsala University Hospital, Department of Surgical Sciences Skorpil, Mikael; Karolinska Institutet, Department of Molecular Medicine and Surgery Sköldenberg, Olof; Karolinska Institute, Department of Clinical Sciences, Danderyd Hospital Hedbeck, Carl Johan; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital Jonsson, Kenneth; Uppsala University Hospital, Department of Surgical Sciences
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	Hamstring, Hamstring Tendons, Randomized Controlled Trial, Magnetic

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	resonance imaging < RADIOLOGY & IMAGING, Patient reported Outcome Measure, Muscle strength

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# The Proximal Hamstring Avulsion Clinical Trial (PHACT)- a randomised controlled non-inferiority trial of operative versus non-operative treatment of proximal hamstrings avulsions: study protocol

---

## Authors:

Elsa Pihl<sup>1</sup>, Målfrid Holen Kristoffersen<sup>2</sup>, Anne-Mari Rosenlund<sup>3</sup>, Sofia Laszlo<sup>4</sup>, Mida Berglöf<sup>1</sup>, Eva Ribom<sup>4</sup>, Karl Eriksson<sup>5</sup>, Frede Frihagen<sup>3</sup>, Ville M Mattila<sup>6</sup>, Jörg Schilcher<sup>7</sup>, Martin Eklund<sup>8</sup>, Greta Snellman<sup>4</sup>, Mikael Skorpil<sup>9</sup>, Olof Sköldenberg<sup>1</sup>, Carl Johan Hedbeck<sup>1</sup>, Kenneth B Jonsson<sup>4</sup>.

<sup>1</sup> Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Orthopaedics, SE-171 77 Stockholm, Sweden

<sup>2</sup> Department of Orthopaedic Surgery, Haukeland University Hospital, N 5021 Bergen, Norway.

<sup>3</sup> Division of Orthopaedic Surgery, Oslo University Hospital, N-0450 Oslo, Norway.

<sup>4</sup> Department of Surgical Sciences, Uppsala University Hospital, SE-751 85 Uppsala, Sweden

<sup>5</sup> Karolinska Institutet Department of clinical science and education Södersjukhuset, Department of Orthopaedics Södersjukhuset, SE-188 83 Stockholm, Sweden

<sup>6</sup> Department of Orthopaedics, Tampere University Hospital, F-33321, Tampere, Finland

<sup>7</sup> Department of Orthopaedic Surgery and Department of Clinical and Experimental Medicine, University Hospital Linköping, SE-58185 Linköping, Sweden

<sup>8</sup> Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, SE-171 77 Stockholm, Sweden

<sup>9</sup> Karolinska Institutet, Department of Molecular Medicine and Surgery, SE-171 77 Stockholm, Sweden

**Word count: 3986**

**Corresponding author:**

**Dr Elsa Pihl; [elsa.pihl@ki.se](mailto:elsa.pihl@ki.se)**

## Abstract

**Introduction:** The treatment of proximal hamstring avulsions is controversial. While several trials have investigated the outcome for patients treated surgically, there is today no prospective trial comparing operative treatment with non-operative treatment. This protocol describes the design for the Proximal Hamstring Avulsion Clinical Trial (PHACT) - the first randomized controlled trial of operative versus non-operative treatment for proximal hamstring avulsions.

**Methods and analysis:** PHACT is a multicentre randomised controlled trial conducted across Sweden, Norway and Finland. Eligible patients (60 participants/treatment arm) with a proximal hamstring avulsion of at least two of three tendons will be randomized to either operative or non-operative treatment. Participants allocated to surgery will undergo reinsertion of the tendons with suture anchors. The rehabilitation program will be the same for both treatment groups. When patient or surgeon equipoise for treatment alternatives cannot be reached and randomization therefore is not possible, patients will be invited to participate in a parallel observational non-randomized cohort. The primary outcome will be the patient reported outcome measure Perth Hamstring Assessment Tool at 24 months. Secondary outcomes include the Lower Extremity Functional Score, physical performance and muscle strength tests, patient satisfaction and MR imaging. Data analysis will be blinded and intention-to-treat analysis will be preformed.

**Ethics and dissemination:** Ethical approval has been granted by the Ethical Committee of Uppsala University (DNR: 2017-170) and by the Norwegian ethical board (REC: 2017/1911). The study will be conducted in agreement with the Helsinki declaration. The findings will be disseminated in peer-reviewed publications.

**This study is registered at ClinicalTrials.gov**

Trial Registration Number: NCT03311997

Recruitment Status: Recruiting

First Posted: October 2017

Last update posted February 2019

**Strength and limitations of this study**

- This is the first randomized clinical trial on operative versus non-operative treatment of proximal hamstring avulsions.
- The multicentre design will support external validity and implementation.
- The treatment outcome will be assessed with a hamstring specific validated PROM, objective functional tests and imaging.
- Owing to the type of interventions, blinding of the patients and treatment providers is not possible.

**Introduction**

The treatment of proximal hamstring avulsions is controversial. The literature suggests that surgical treatment is the treatment of choice. For example, in a recent systematic review by Bodendorfer et al. <sup>1</sup> it is claimed that surgically treated patients have better results in psychometric scores, functional- and strength tests than non-surgically treated patients. However, existing literature may be biased. The studies conducted so far are mainly retrospective case series <sup>1 2</sup> and have only occasionally used validated outcome measures, such as Harris Hip Score <sup>3</sup> and Lower Extremity Functional Scale <sup>3-5</sup>. The Perth Hamstring Assessment Tool (PHAT) <sup>6</sup> is designed and validated for follow up of patients with hamstring avulsion <sup>6</sup>, but was only recently developed.

Bodendorfer et al. <sup>1</sup> only found 28 non-surgical treated patients compared to 767 surgical treated patients to include in their review, suggesting a publication bias in the existing literature and providing limited power for comparisons between the surgically and non-surgically treated patients. In the light of the apparent lack of comparative studies one needs to be aware of surgical complication rates when suggesting operative treatment. With

1  
2  
3 a reported aggregated complication rate as high as 23% in the surgically treated group <sup>1</sup>,  
4 surgery cannot be considered harmless.

5  
6  
7 The aim of this prospective, multicentre, randomized controlled trial is to provide  
8 reliable evidence on how to treat physically active patients, 30 to 70 years of age, with  
9 proximal hamstring avulsions. We will use PHAT <sup>6</sup> at 24 months post treatment allocation as  
10 our primary outcome measure.  
11  
12  
13  
14  
15

## 16 **Methods and analysis**

### 17 **Study design and setting**

18  
19 The Proximal Hamstring Avulsion Clinical Trial (PHACT) is a multicentre, prospective,  
20 preference-tolerant, randomised, controlled, non-inferiority trial with two treatment arms.  
21 The protocol was developed in accordance with Standard Protocol Items: Recommendations  
22 for Interventional Trials and Template for Intervention Description and Replication  
23 statements <sup>7 8</sup>.  
24  
25  
26  
27  
28  
29

30 The study is conducted in cooperation with Swedish Orthopaedic Trauma Society and  
31 has eleven study sites at orthopaedic departments across Sweden, Norway and Finland.  
32 Inclusion started in September 2017 and recruitment is expected to finalise in 2021, which  
33 would allow for read-out of the primary endpoint in 2023.  
34  
35  
36  
37  
38

### 39 **Recruitment strategy**

40 Patients with proximal hamstring avulsions that are diagnosed or referred to the  
41 orthopaedic department at one of the eleven hospitals will be screened for participation in  
42 the study. Eligible patients are invited to participate and provided with oral and written  
43 information. Thereafter patients are asked to sign a written informed consent statement  
44 before any study procedure occurs.  
45  
46  
47  
48  
49  
50

### 51 **Patients**

52 Patients must fulfil all the inclusion criteria and must not have any exclusion criteria to be  
53 eligible for randomization.  
54  
55

- 56 • Age at injury between 30 and 70 years
- 57  
58  
59  
60



- Physical examination supports the diagnosis; e.g. a positive hip extension test, palpable defect and/or local tenderness and hematoma
- MRI shows a complete acute avulsion of at least two of three tendons from the footprint at the ischial tuberosity
- Patient has a moderate to high activity level
- Patient has linguistic and mental ability to understand the rehabilitation program explained in Swedish, Norwegian, Finnish or English
- Time from injury to inclusion in study is less than 4 weeks

### ***Exclusion criteria***

- Diabetes with secondary complications
- Previous major lower extremity injury or disease with sequelae
- Moderate or severe liver, pulmonary, kidney, psychiatric or heart disease that significantly increases the risk of complications after operative treatment
- Severe obesity (BMI>35)
- Alcohol or substance abuse
- High energy injury or combinations of injuries affecting the lower extremity

### ***Intervention***

We will randomly assign patients to either operative treatment (n=60) with suture anchor reinsertion of the tendons to the footprint at the ischial tuberosity or to non-operative treatment (n=60). Both groups will follow the same standardized rehabilitation protocol.

To minimize bias by indication, we will offer the patients that are eligible but where patient or doctor equipoise to treatment cannot be reached to participate in a parallel follow up cohort with identical treatment options and follow-up. In the parallel cohort, the patients/surgeons preferred treatment is provided.

### ***Surgical procedure***

Patients allocated to the operative group will undergo surgery at the earliest convenient time but no later than 6 weeks after the injury. The surgeon may choose whether to make a longitudinal or transversal skin incision. The proximal ends of the avulsed tendons are identified and after dissection they are reattached to the ischial tuberosity using at least two

1  
2  
3 suture anchors. Data on the surgical approach, the number of suture anchors and their  
4 manufacturer as well as the surgeon's intra-operative assessment of retraction and the  
5 number of tendons involved will be collected.  
6  
7

### 8 9 **Rehabilitation**

10  
11 The rehabilitation protocol is based on a previously published rehabilitation protocol<sup>9</sup> and  
12 will be the same for both treatment allocations. In brief: No brace is used. Full weight  
13 bearing is allowed. The patients are instructed to keep their stride length short, and to avoid  
14 sitting and any motion that stretches the hamstring for the first three weeks. Patients are  
15 instructed to perform isometric exercises of the quadriceps and gluteal muscles to avoid  
16 muscle atrophy. After two weeks, isometric contractions of the hamstring muscles are  
17 allowed and progressed with cautious dynamic exercises during week four. Specific  
18 hamstring strengthening exercises are begun after five weeks.  
19  
20  
21  
22  
23  
24  
25

### 26 27 **Study outcomes**

#### 28 29 **Primary outcome**

30  
31 The primary outcome measure will be the patient reported PHAT score<sup>6</sup> at 24 months. PHAT  
32 is a condition specific questionnaire with maximum score 100, with a higher score  
33 corresponding to higher function. The questionnaire uses a visual analogue scale for pain  
34 scores during different activities, as well as categorical scores for activity levels and  
35 tenderness, and has been shown to be sensitive to clinical changes<sup>10</sup>.  
36  
37  
38  
39  
40

#### 41 42 **Secondary outcomes**

##### 43 *Additional patient reported outcomes*

44  
45 The Lower Extremity Functional Scale (LEFS)<sup>11</sup> will be used to assess patient reported  
46 outcome. LEFS is a reliable, valid and responsive tool for assessing functional status in  
47 several populations with lower extremity musculoskeletal conditions<sup>11 12</sup>. Information  
48 regarding physical activity level will be collected using the short form of International  
49 Physical Activity Questionnaire, IPAQ-SF<sup>13 14</sup>. Furthermore, data on general satisfaction,  
50 return to work and return to sports will be collected.  
51  
52  
53  
54  
55

##### 56 *Functional tests and muscle strength tests*

57  
58 The functional performance will be assessed through the timed step test<sup>15</sup>, which is a test  
59 previously validated for knee arthroplasty patients and the single leg hop test, which is a  
60

1  
2  
3 performance-based test validated in anterior cruciate ligament trials <sup>16</sup>. Measurement of  
4 maximum kinetic force (Newton, N) will be conducted using a handheld isometric  
5 dynamometer (microFET 2; Hoggan health industries)<sup>17</sup>. Study sites equipped with a  
6 computer based isokinetic dynamometer, BiodexTM<sup>18 19</sup>, will assess peak torque (N) and  
7 total workload (Joule, J) of the hamstrings. All strength and functional performance tests will  
8 be reported with ratio of injured/uninjured leg, with the uninjured leg serving as reference  
9 for each subject.  
10  
11  
12  
13  
14  
15

### 16 *Imaging outcomes*

17  
18 Magnetic Resonance Imaging, MRI, will be used at 24 months to evaluate the entire thigh  
19 muscle volume and to assess muscle and tendon quality. We will use the uninjured side as  
20 reference for each subject.  
21  
22  
23

### 24 **Data collection procedure**

25  
26 At inclusion demographic data activity at injury and time from injury to treatment is  
27 collected. Follow-up visits are planned at 3, 6, 12 and 24 months. A study nurse will provide  
28 a set of questionnaires for the patients to fill out. The nurse will also scan the patients'  
29 charts for adverse events or complications. A physiotherapist that is blinded to the  
30 intervention will perform the strength and functional test at 6, 12 and 24 months. At the 24-  
31 month follow-up, MRI of both thighs will be performed.  
32  
33  
34  
35  
36  
37

### 38 **Sample size**

39  
40 Taking into account the cost and risks associated with surgery, and the fact that the  
41 literature clearly recommends surgery, a non-inferiority design was considered appropriate.  
42 Thus, the study aims to demonstrate that non-operative treatment is no worse than  
43 operative treatment by more than the non-inferiority margin.  
44  
45  
46  
47

48 Based on the existing literature the standard deviation of PHAT measurements is  
49 approximately 16-21 <sup>6 20</sup>. A reasonable non-inferiority margin is half of the standard  
50 deviation and this effect size is lower than the minimal detectable change of the PHAT <sup>6</sup>. To  
51 achieve 85% power, with  $\alpha=0.5$ , for demonstrating non-inferiority using a non-inferiority  
52 margin of 10, 50 patients in each arm are required. Heterogeneity of treatment effects is  
53 likely in surgical interventions and is best handled by increasing power. Some crossover and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 loss to follow-up will occur. For these reasons, we will continue inclusion until at least 60  
4 patients in each group has initiated treatment.  
5  
6

### 7 **Randomisation procedure**

8  
9  
10 The REDCap (REDCap Software TM) randomization tool will be used to facilitate  
11 randomisation <sup>21</sup>. Allocation tables with a random block size (2-6), stratified by study site,  
12 were created by a statistician and uploaded blinded into the REDCap project. The  
13 randomisation is permanent and not editable within the participant record and, like all other  
14 activity within REDCap, is tracked and not modifiable in the audit log.  
15  
16  
17  
18  
19

### 20 **Blinding**

21  
22 To minimize ascertainment bias this trial is single-blinded, where the physiotherapist  
23 conducting strength and functional tests at 6, 12 and 24 months will be blinded to the  
24 intervention, by informing the patients not to tell and asking them to wear clothes  
25 concealing the surgery scar. The statistician analysing the data will also be blinded to  
26 treatment arms.  
27  
28  
29  
30  
31

### 32 **Data management**

33  
34 All study data will be collected and managed in a digital case report form, CRF, using REDCap  
35 electronic data capture tools hosted at Karolinska Institutet. REDCap is a secure, web-based  
36 application supporting data capture for research studies, providing: 1) an intuitive interface  
37 for validated data entry; 2) audit trails for tracking data manipulation and export  
38 procedures; 3) automated export procedures for seamless data downloads to common  
39 statistical packages; and 4) procedures for importing data from external sources. <sup>21</sup>  
40  
41  
42  
43  
44

45 Data will be kept securely in order to protect confidentiality before, during and after  
46 the trial. A codebook matching the personal identification number and the trial identification  
47 number is kept at each study site and the trial identification number is noted in the patient's  
48 electronic chart. The study nurses and investigators can log on and enter data directly into  
49 the database. Patients will complete surveys at each visit. Any paper forms used are stored  
50 for cross checking at each study site.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Statistical analysis plan

The flow of patients through the trial is displayed in a CONSORT diagram (Figure 1). The number of patients screened for trial entry; those who are ineligible and the reasons why; number of eligible patients not providing consent; and the number of eligible patients subsequently randomised will be presented. The characteristics of the screened population, the ineligible participants, and eligible participants who consent and do not consent will be summarised. Information regarding the number of surgeons and centres, as well as number of patients treated by each surgeon will be provided. Data on patient eligibility and reasons for withdrawal from treatment or the trial will be summarised. Baseline patient characteristics will be summarized using descriptive statistics; counts for categorical variables and mean/median and inter-quartile range for continuous variables.

Primary analyses will be by intention-to-treat. However, since ITT analyses can be anti-conservative for non-inferiority trials, we will also conduct per-protocol and as-treated analyses. Cases will only be considered treatment cross-overs if the randomly assigned treatment is changed by patient preferences. Non-operative treated patients that are treated operatively due to late complaints (>3 mo. after inclusion) will not be considered cross-overs.

All analyses will be conducted blinded for treatment allocation. All statistical tests will be two-sided with an  $\alpha$  of 0.05. Differences between groups in continuous skewed main outcome variables will be analysed by the Mann-Whitney U-test, and by the t-test when variables are from a symmetrical distribution. Results will be presented with 95% confidence intervals. Two-way-tables with the chi-square test will be used for dichotomous variables. No adjustment of p-values for multiple comparisons (secondary analyses) will be undertaken.

In secondary analyses, multivariate regression models will be used to analyse the primary outcome (PHAT score at 24 months follow-up). The main variables of interest included are; the intervention, age, sex, study site and the degree of tendon retraction. We will also jointly analyse all timepoints in a linear mixed model (to adjust for within-patient correlations). Patients will be treated as a random effects, and time points, randomization arm, age at baseline, sex, and degree of tendon retraction will be included as fixed effects. As further secondary analyses, the randomized and observational cohorts will be analysed

1  
2  
3 together using propensity scores adjustment (the randomized patients will get propensity  
4 score 0.5). The propensity score will be based on age, sex, study site, IPAQ and the degree of  
5 tendon retraction.  
6  
7

8 We will test for heterogeneity of treatment effects by testing for significant  
9 interactions in the following subgroups: Tendon retraction  $> 2$  cm vs  $\leq 2$  cm and age  $> 50$   
10 years vs  $\leq 50$  years.  
11  
12  
13

14 Missing data can occur in two different ways in the study: (1) Questions in the PHAT  
15 questionnaire can be left unanswered; and (2) patients can miss specific follow-up visits or  
16 drop out of the study altogether. Missing PHAT score questions will be imputed based on the  
17 answered questions. Missed follow-up visit at 24 months will be handled using a multiple  
18 imputed model for the primary analysis. The multiple imputation protocol will be based on a  
19 longitudinal model for predicting PHAT at 24 months based on the PHAT score recorded at  
20 previous time points together with patient age, sex, and degree of tendon retraction. The  
21 mixed effects model handles data missing at random seamlessly and no imputation will be  
22 needed for that specific analysis. We will test the robustness of the results to data not  
23 missing at random by assuming a missingness model where missingness is associated with  
24 PHAT score.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Adverse events and complications**

36 At follow-up, questions with the aim of identifying adverse events and serious adverse  
37 events will be provided. Medical records will also be checked for adverse effects. Undesired  
38 events such as surgical site infections, neurological sequelae, thromboembolism, re-rupture  
39 or failure and hypertrophic scarring in surgical patients are defined as adverse effects.  
40 Serious adverse effects are defined as events resulting in death, hospitalization or  
41 threatening life, i.e. pulmonary embolism, sepsis or cardiovascular complications.  
42  
43  
44  
45  
46  
47  
48

### 49 **Patient involvement**

50 Patients were not formally involved in designing the study protocol. In the process of  
51 designing the study protocol and selecting the primary outcome a few patients were  
52 interviewed in clinical practice. Patients have been invited to participate in monitor meeting  
53 with researchers from the participating sites present. The participants will receive a written  
54 summary of main findings when the study is finished.  
55  
56  
57  
58  
59  
60

## Ethics and dissemination

Ethical approval has been granted by the Ethical Committee of Uppsala University (DNR: 2017-170) and the Norwegian Regional Ethical Committee (REC: 2017/1911). The study will be conducted in agreement with the Helsinki declaration.

As both treatment options are accepted in the catchment area for the study, the randomization procedure was deemed ethically acceptable. The results will provide evidence-based treatment algorithms for future patients.

The primary study results will be submitted for publication to an international, peer-reviewed journal, regardless of whether the results are positive, negative or inconclusive in relation to the study hypothesis.

## References

1. Bodendorfer BM, Curley AJ, Kotler JA, et al. Outcomes After Operative and Nonoperative Treatment of Proximal Hamstring Avulsions: A Systematic Review and Meta-analysis. *The American journal of sports medicine* 2017;363546517732526. doi: 10.1177/0363546517732526
2. van der Made AD, Wieldraaijer T, Kerkhoffs GM, et al. The hamstring muscle complex. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA* 2015;23(7):2115-22. doi: 10.1007/s00167-013-2744-0 [published Online First: 2013/11/06]
3. Chahal J, Bush-Joseph CA, Chow A, et al. Clinical and magnetic resonance imaging outcomes after surgical repair of complete proximal hamstring ruptures: does the tendon heal? *The American journal of sports medicine* 2012;40(10):2325-30. doi: 10.1177/0363546512453298
4. Hofmann KJ, Paggi A, Connors D, et al. Complete Avulsion of the Proximal Hamstring Insertion: Functional Outcomes After Nonsurgical Treatment. *The Journal of bone and joint surgery American volume* 2014;96(12):1022-25. doi: 10.2106/jbjs.m.01074 [published Online First: 2014/06/22]
5. Skaara HE, Moksnes H, Frihagen F, et al. Self-reported and performance-based functional outcomes after surgical repair of proximal hamstring avulsions. *The American journal of sports medicine* 2013;41(11):2577-84. doi: 10.1177/0363546513499518 [published Online First: 2013/08/31]
6. Blakeney WG, Zilko SR, Edmonston SJ, et al. Proximal hamstring tendon avulsion surgery: evaluation of the Perth Hamstring Assessment Tool. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA* 2017;25(6):1936-42. doi: 10.1007/s00167-016-4214-y



- 1  
2  
3 7. Hoffmann TC, Glasziou PP, Boutron I, et al. [Better Reporting of Interventions: Template  
4 for Intervention Description and Replication (TIDieR) Checklist and Guide].  
5 *Gesundheitswesen* 2016;78(3):e174. doi: 10.1055/s-0037-1600948 [published Online  
6 First: 2016/03/01]  
7
- 8 8. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard  
9 protocol items for clinical trials. *Rev Panam Salud Publica* 2015;38(6):506-14.  
10 [published Online First: 2016/07/22]  
11
- 12 9. Askling CM, Koulouris G, Saartok T, et al. Total proximal hamstring ruptures: clinical and  
13 MRI aspects including guidelines for postoperative rehabilitation. *Knee surgery,*  
14 *sports traumatology, arthroscopy : official journal of the ESSKA* 2013;21(3):515-33.  
15 doi: 10.1007/s00167-012-2311-0 [published Online First: 2012/12/12]  
16
- 17 10. Blakeney WG, Zilko SR, Edmonston SJ, et al. A prospective evaluation of proximal  
18 hamstring tendon avulsions: improved functional outcomes following surgical repair.  
19 *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*  
20 2017;25(6):1943-50. doi: 10.1007/s00167-017-4475-0 [published Online First:  
21 2017/03/11]  
22
- 23 11. Binkley JM, Stratford PW, Lott SA, et al. The Lower Extremity Functional Scale (LEFS):  
24 scale development, measurement properties, and clinical application. North  
25 American Orthopaedic Rehabilitation Research Network. *Physical therapy*  
26 1999;79(4):371-83. [published Online First: 1999/04/14]  
27
- 28 12. Mehta SP, Fulton A, Quach C, et al. Measurement Properties of the Lower Extremity  
29 Functional Scale: A Systematic Review. *J Orthop Sports Phys Ther* 2016;46(3):200-16.  
30 doi: 10.2519/jospt.2016.6165 [published Online First: 2016/01/28]  
31
- 32 13. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-  
33 country reliability and validity. *Medicine and science in sports and exercise*  
34 2003;35(8):1381-95. doi: 10.1249/01.Mss.0000078924.61453.Fb [published Online  
35 First: 2003/08/06]  
36
- 37 14. Lee PH, Macfarlane DJ, Lam TH, et al. Validity of the International Physical Activity  
38 Questionnaire Short Form (IPAQ-SF): a systematic review. *The international journal of*  
39 *behavioral nutrition and physical activity* 2011;8:115. doi: 10.1186/1479-5868-8-115  
40 [published Online First: 2011/10/25]  
41
- 42 15. Marmon AR, McClelland JA, Stevens-Lapsley J, et al. Single-step test for unilateral limb  
43 ability following total knee arthroplasty. *J Orthop Sports Phys Ther* 2013;43(2):66-73.  
44 doi: 10.2519/jospt.2013.4372  
45
- 46 16. Reid A, Birmingham TB, Stratford PW, et al. Hop testing provides a reliable and valid  
47 outcome measure during rehabilitation after anterior cruciate ligament  
48 reconstruction. *Physical therapy* 2007;87(3):337-49. doi: 10.2522/ptj.20060143  
49 [published Online First: 2007/02/22]  
50
- 51 17. Reurink G, Goudswaard GJ, Moen MH, et al. Strength Measurements in Acute Hamstring  
52 Injuries: Intertester Reliability and Prognostic Value of Handheld Dynamometry. *J*  
53 *Orthop Sports Phys Ther* 2016;46(8):689-96. doi: 10.2519/jospt.2016.6363 [published  
54 Online First: 2016/05/14]  
55
- 56 18. Drouin JM, Valovich-mcLeod TC, Shultz SJ, et al. Reliability and validity of the Biodex  
57 system 3 pro isokinetic dynamometer velocity, torque and position measurements.  
58 *Eur J Appl Physiol* 2004;91(1):22-9. doi: 10.1007/s00421-003-0933-0 [published  
59 Online First: 2003/09/26]  
60



- 1  
2  
3 19. Pincivero DM, Lephart SM, Karunakara RA. Reliability and precision of isokinetic strength  
4 and muscular endurance for the quadriceps and hamstrings. *International journal of*  
5 *sports medicine* 1997;18(2):113-7. doi: 10.1055/s-2007-972605 [published Online  
6 First: 1997/02/01]  
7  
8 20. Best R, Eberle J, Beck F, et al. [Surgical Refixation after Proximal Hamstring Tendon  
9 Avulsion Injuries: Does the Time of Surgery Influence Functional Outcomes?].  
10 *Sportverletzung Sportschaden : Organ der Gesellschaft für Orthopädisch-*  
11 *Traumatologische Sportmedizin* 2017;31(3):160-66. doi: 10.1055/s-0043-113211  
12 [published Online First: 2017/09/05]  
13  
14 21. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a  
15 metadata-driven methodology and workflow process for providing translational  
16 research informatics support. *Journal of biomedical informatics* 2009;42(2):377-81.  
17 doi: 10.1016/j.jbi.2008.08.010 [published Online First: 2008/10/22]  
18  
19  
20  
21  
22

### 23 **Authors' contributions: state how each author was involved in writing the protocol.**

24  
25  
26 All authors have contributed to the design of this trial protocol. E Pihl, CJ Hedbeck and K B  
27 Jonsson have initiated the project. K B Jonsson is the primary investigator. The protocol was  
28 drafted by E Pihl and K B Jonsson and was refined by M Holen Kristofferssen, A-M  
29 Rosenlund, M Berglöf, E Ribom, K Eriksson, F Frihagen, G Snellman, J Schilcher, M Eklund, V  
30 M Mattila, M Skorpil, O Sköldenberg and CJ Hedbeck. Statistical advice was provided by  
31 Eklund. M Berglöf and E Ribom designed the protocol for physical functional tests and the  
32 rehabilitation program. M Skorpil, E Pihl and S Laszlo developed protocol for the imaging  
33 outcomes. S Laszlo was responsible for drafting the manuscript. All authors have read and  
34 approved the final manuscript.  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **Collaborators**

45  
46 The PHACT collaborative study group consists of all local investigators who are responsible  
47 for the execution of the trial and valid data gathering. They have all read and approved the  
48 final manuscript.  
49

### 50 **Funding**

51  
52  
53 This work was supported by:

54  
55 AFA Insurance.

56  
57 Centrum för idrottsforskning, CIF, grant number (P2019-0155).  
58  
59  
60

1  
2  
3 Landstingets Ömsesidiga Försäkringsbolag, LÖF, insurance company owned by its policy  
4 owners, the Swedish counties and regions.

5  
6 Östergötland County Council.  
7  
8  
9  
10

### 11 **Competing interests statement.**

12  
13  
14 We have no competing interest to declare.  
15  
16

### 17 **Legends**

18  
19  
20 Figure 1. Flow chart. This study illustrates the study design  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Screening

Patient with proximal hamstrings injury

**Excluded**  
-not meeting inclusion criteria  
-meeting exclusion criteria

Enrollment

Eligible participants

**Excluded**  
- do not wish to enter

Participants and doctor reaches equipoise to treatment

Yes

No

RCT

Observational cohort  
Treatment by preference

Allocation

Operative treatment

Non-operative treatment

Follow-up

3 months: PHAT, LEFS, IPAQ-SF, adverse events

6 and 12 months: PHAT, LEFS, IPAQ-SF, adverse events, physical performance

24 months: PHAT, LEFS, IPAQ-SF, adverse events, physical performance, MRI

Analysis

Primary outcome : PHAT at 24 months